<DOC>
	<DOCNO>NCT01093651</DOCNO>
	<brief_summary>We test safety new class anti-diabetes compound ( DPPIV-inhibitors ) people live HIV . Future trial examine efficacy treat diabetes reduce cardiovascular disease risk people live HIV .</brief_summary>
	<brief_title>Dipeptidyl Peptidase-4 Inhibition Immune Function HIV</brief_title>
	<detailed_description>Human immunodeficiency virus ( HIV ) -infection treatment antiretroviral therapy associate several cardiometabolic risk factor ; insulin resistance , diabetes , dyslipidemia , central adiposity , increase risk MI stroke . A new class drug use treat type 2 diabetes introduce ; Dipeptidyl peptidase-IV ( DPPIV ) -inhibitors ( Januvia® , Onglyza® , alogliptin ) . Dipeptidyl peptidase-IV ( DPPIV ) -inhibition could safe effective therapy HIV-associated insulin resistance diabetes . However , safety data exist . The research question : If HIV+ adult stable immunologic ( CD4+ T-cell count &gt; 350 cells/μL ) virologic ( plasma HIV RNA &lt; 50 copies/mL ) function give DPPIV-inhibitor would CD4+ T-cell count plasma HIV RNA level increase , decrease , stay ? Theoretically , DPPIV-inhibition could enhance immune system increase SDF-1α level ; potent inhibitor HIV-entry T-cells , harm HIV+ immune system inactivate CD26 immune cell . We hypothesize DPPIV-inhibition harm immune system HIV+ people . We propose blind randomize control pilot safety trial FDA-approved DPPIV-inhibitor virologically- immunologically-stable HIV+ men woman . We monitor CD4+ T-cell count , plasma HIV RNA level , immune activation marker , safety outcome ( lipid/lipoprotein profile , blood pressure , kidney liver function ) 4-6 month DPPIV-inhibitor exposure v placebo 20 HIV+ adult . If safety confirm , efficacy DPPIV-inhibition HIV+ insulin resistance test future trial examine potential glucoregulatory cardiovascular benefit .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Thirty 1865 yr old HIVinfected men woman ( source documentation HIV status ) stable antiretroviral therapy ( cART ) regimen 2 . Have stable ( least past 12months ) immunologic ( &gt; 350 CD4+ Tcells/µL ) virologic ( &lt; 50 copy HIV RNA/mL ) status . 3 . BMI 1842kg/m2 ; 4 . Normal blood chemistry least 1 month prior enrollment ; 5 . Platelet count &gt; 30,000/mm3 , absolute neutrophil count &gt; 750/mm3 , transaminase &lt; 2.5x upper limit normal ( ULN ) . 6 . Longterm nonprogressors ( ART ) eligible . 1 . CD4+ Tcell count &lt; 350 cells/µL detectable plasma HIV RNA ( &gt; 50 copy HIV RNA/mL ) within past 12months . During study , CD4+ Tcell count decline &gt; 100 cells/µL , plasma HIV RNA become detectable ( &gt; 50 copy HIV RNA/mL repeat analysis 2wks apart ) , participant denies lapse antiHIV medication regimen , study medication stop adverse event document . If time study , two participant experience reduction Tcell count &gt; 100 cells/µL , plasma HIV RNA level become detectable ( &gt; 50 copy HIV RNA/mL repeat analysis 2wks apart ) , confirm ( unblinding ) receive sitagliptin , study stop serious safety concern . 2 . Systemic , secondary opportunistic infection within past 12months . 3 . Fasting glucose intolerance ( FBG &gt; 100mg/dL ) , fast hyperinsulinemia ( &gt; 15µU/mL ) , fast insulin resistance ( Homeostasis model insulin resistance ( HOMA ) &gt; 3.0 ) . Any agent might alter glucose metabolism ( insulin , TZDs , metformin , glucocorticoid , sulfonylurea , corticosteroid , megace , rhGH , GHsecretagogue ) 3 month prior enrollment time enrollment . Volunteers T2DM , IDDM diabetic ketoacidosis enrol . 4 . History serious CV disease NYHA Functional Class III IV , ( e.g. , recent MI , unstable angina , edema , CHF , CAD , CABG , valve disease ( murmur ) , stroke , uncontrolled high blood pressure ( rest &gt; 160/95 mmHg ) , irregular heart rhythm , rest STsegment depression &gt; 1mm ) . Treatment medication CV condition ( cardiac glycoside α ßblockers ) . Some antihypertensive medication ( calciumchannel blocker , diuretic , angiotensin II receptor blocker ( ARB ) , angiotensin convert enzyme inhibitor ( ACE ) ) permit . 5 . Moderate severe renal insufficiency . Serum creatinine &gt; 1.7 mg/dL ( men ) &gt; 1.5 mg/dL ( woman ) . 6 . Known allergy hypersensitivity DPPIVinhibitors . 7 . Plan change antiHIV medication regimen prophylaxis opportunistic infection within 6months start study.Transitions among efavirenzbased regimen allow ( e.g. , Efavirenz + lamivudine + zidovudine ( combivir ) Efavirenz + emtricitabine + tenofovir ( Atripla ) ) . 8 . Lipidlowering medication permit ( fibrate statin niacin ) , must stable agent least 3 month prior enrollment . Lipidlowering agent start treatment period . 9 . Chronic hepatitis B infection ( HB surface antigen positive ) . Active hepatitis C infection ( detectable Hep C RNA ) . Those cleared hepatitis B C infection eligible . 10 . Hematocrit &lt; 34 % men &lt; 25 % woman symptom ( fatigue , `` tiredlegs '' , shortness breath ) . Hemoglobin &lt; 10 gm/100ml symptom . 11 . Nausea , vomit , diarrhea ( &gt; 4 loose stools/day ) unresponsive treatment . History eat disorder significant GIdisease . 12 . Pregnant nursing mother . Women must agree use acceptable form birth control study . If birth control pill use , woman must stable medication least 6 month prior enrollment . 13 . Active malignancy treatment chemotherapeutic agent radiation therapy ( within past 12 month ) . 14 . &gt; 10 % unintentional body weight loss 12 month prior enrollment . 15 . `` Blinded '' investigational drugs/medications 3 month prior enrollment unblinded enrollment . Openlabel investigational drug permit ( within past 3 month , plan stop enrollment know affect glucose , lipid , adipose tissue liver metabolism ) . 16 . Over counter agent might alter glucose , lipid , adipose tissue metabolism ( e.g. , creatine monohydrate , chromium picolinate , amino acid/protein supplement , medium longchain fatty acid ) within 1 month enrollment . These supplement permit treatment period . 17 . Reduced cognitive function/unable provide voluntary inform consent . Prisoners exclude . 18 . Active substance abuse physicianscientist believe may compromise safety , compliance , interfere study drug data interpretation . 19 . Any cytokine anticytokine therapy 3 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>